
COVID-19 may have accelerated the adoption of RBQM, but it is the intrinsic benefits that are cementing its continued use.
Patrick Hughes is Co-Founder, Chief Commercial Officer, CluePoints
COVID-19 may have accelerated the adoption of RBQM, but it is the intrinsic benefits that are cementing its continued use.
What started as an initiative called Risk-Based Monitoring several years ago is now evolving into Risk-Based Quality Management of clinical trials with a much wider impact to the pharma industry.
Published: March 13th 2019 | Updated: